Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Polyacrylic acid of PAA have been prepared that are responsive to pH and temperature stimuli, demonstrating the possibility to be used for drug delivery purposes. ATRP has been used to growth PAA brushes from the surface. One reported approach was with surface-initiated ATRP of tert-butyl acrylate that was subsequently deprotected through pyrolysis to form the carboxylic acid. These PAA brushes can form chelate complex with silver and can therefore exhibit antibacterial activity. Polyacrylic acid Poly(acrylic acid) (PAA; trade name Carbomer) is a synthetic high-molecular weight polymers of acrylic acid. The IUPAC name is poly(1-carboxyethylene. They may be homopolymers of acrylic acid, or